Zenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
November 12, 2024 07:10 ET
|
Zenas BioPharma
-Completed initial public offering, raising $258.7 million in gross proceeds, to fund the expanded clinical development of lead product candidate, obexelimab, and support company growth strategy- ...
Zenas BioPharma Completes Targeted Enrollment of the Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)
November 12, 2024 07:05 ET
|
Zenas BioPharma
-INDIGO is the largest clinical trial conducted in patients living with IgG4-RD- -Topline INDIGO results expected by the end of 2025- WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Zenas...
Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences
November 07, 2024 07:05 ET
|
Zenas BioPharma
WALTHAM, Mass, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the...
Zenas BioPharma Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in Initial Public Offering
September 19, 2024 16:15 ET
|
Zenas BioPharma
WALTHAM, Mass., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas”), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical company committed to being a leader in the development...
Zenas BioPharma Announces Pricing of Upsized Initial Public Offering
September 12, 2024 22:37 ET
|
Zenas BioPharma
WALTHAM, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas”), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical company committed to being a leader in the development...
Zenas BioPharma Appoints Orlando Oliveira as Chief Commercial Officer
July 01, 2024 07:00 ET
|
Zenas BioPharma
WALTHAM, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immunology-based...
Zenas BioPharma Announces Upsized $200 Million Series C Financing to Advance Mid- and Late-Stage Immunology-Focused Clinical Development Programs
May 07, 2024 07:00 ET
|
Zenas BioPharma
Financing led by SR One, NEA, Norwest Venture Partners, and Delos Capital with significant participation from Enavate Sciences, Longitude Capital, and other new and existing investors Proceeds to...
Zenas BioPharma beruft Patricia Allen in den Verwaltungsrat
March 06, 2024 18:59 ET
|
Zenas BioPharma
WALTHAM, Massachusetts, March 07, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, ein weltweit tätiges Biopharmazieunternehmen, dessen Ziel eine führende Rolle in der Entwicklung und Kommerzialisierung...
Zenas BioPharma 任命 Patricia Allen 為董事會成員
March 06, 2024 18:59 ET
|
Zenas BioPharma
沃爾瑟姆，馬薩諸塞州, March 07, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma 是一家全球生物製藥公司，致力於成為炎症與免疫定向療法開發和商業化的領導者，今日宣布任命 Patricia Allen 為董事會成員，同時她還將擔任審計委員會主席。加入 Zenas 董事會時，Allen...
Zenas BioPharma 任命 Patricia Allen 为董事会成员
March 06, 2024 18:59 ET
|
Zenas BioPharma
沃尔瑟姆，马萨诸塞州, March 07, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma 是一家全球生物制药公司，致力于成为炎症与免疫定向疗法开发和商业化的领导者，今日宣布任命 Patricia Allen 为董事会成员，同时她还将担任审计委员会主席。加入 Zenas 董事会时，Allen...